Anti Coagulation System

Scope, procedure and submissions

Id

C444337

Status

complete

Procurement Method

direct

Procurement Method Details

Direct award

Why this procedure was chosen

-Following an assessment of the UK market, DAWN AC has been identified as the only supplier able to meet the Trust’s mandatory technical, clinical, and interoperability requirements for an acute NHS anticoagulation service. Other systems assessed do not provide the necessary functionality to safely manage both warfarin and direct oral anticoagulant (DOAC) patients at scale, nor do they support required integrations with existing Trust electronic patient record and laboratory systems. This constitutes an absence of genuine competition for technical reasons. -Alternative systems were reviewed and determined not to be reasonable substitutes, as they are primarily designed for primary care or low‑volume use and lack essential features required in an acute hospital setting, including comprehensive DOAC management, automated dosing support, patient communication functionality, and full system interoperability. As such, no alternative solution can meet the Trust’s minimum requirements without unacceptable clinical, operational, and patient safety risk. - The incumbent RAID system is being withdrawn and will no longer be supported after 30 November 2026. The Trust must implement a replacement system within a defined timeframe to ensure continuity of a critical, high‑risk clinical service supporting approximately 7,000 patients. A competitive procurement would not deliver a viable alternative solution and would not change the outcome, as only one supplier is capable of meeting the Trust’s requirements. The direct award is therefore proportionate and necessary.

Published risks

If the system is not replaced, the Trust will be unable to safely operate the anticoagulation service once the RAID system is withdrawn and support ends, as there would be no viable mechanism to manage dosing, monitoring, reviews, or patient records for a high‑risk medication pathway. This would likely result in suspension or closure of the service, creating significant patient safety risks, loss of continuity of care for approximately 7,000 patients, and potential clinical harm. In addition, the Trust would face a loss of associated income, workforce disruption, and reputational and regulatory risk arising from the inability to meet its clinical and statutory obligations.

Lots and requirements

Published documents

Buyer, suppliers and contacts

Award information

Recorded locations

• Buyer location · Swindon · UKK14 · SN3 6BB · United Kingdom